Wedbush restated their neutral rating on shares of IGM Biosciences (NASDAQ:IGMS – Free Report) in a report issued on Friday ...

Royal Bank of Canada lowered shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from an outperform rating to a sector ...

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company ...

Fintel reports that on January 10, 2025, Jefferies downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

The company is reducing its workforce by 73% and evaluating strategic alternatives to preserve shareholder value.

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...